emerald: elacestrant vs. soc for patients with er her2- metastatic breast cancer
Published 2 years ago • 1.6K plays • Length 2:03Download video MP4
Download video MP3
Similar videos
-
0:46
update of emerald by duration of cdk4/6i in metastatic setting: elacestrant v soc in er /her2- mbc
-
1:27
emerald: elacestrant vs physicians choice in er /her2- breast cancer
-
2:21
updated results by duration of prior cdk4/6i in the met setting of the phase iii emerald trial
-
4:50
expert report on tackling resistance to cdk4/6 inhibitors in er /her2-metastatic breast cancer
-
3:01
assessing elacestrant in ctdna-positive patients with er breast cancer
-
2:35
what does the future hold for serds in er breast cancer?
-
0:30
the impact of the emerald trial results based on duration of prior cdk4/6i in the metastatic setting
-
2:15
treatment strategies for her2 metastatic breast cancer
-
3:17
faslodex shots
-
3:00
orserdu tablets how to use: uses, dosage, side effects, contraindications
-
16:10
emerald study lead to the elacestrant fda approval - oncbrothers in discussion w/ dr. aditya bardia
-
3:24
elacestrant shows improved pfs in patients with er-positive/her2-negative metastatic breast cancer
-
2:06
elacestrant significantly prolongs pfs for er /her2- metastatic bc without prior chemotherapy pts
-
0:51
ember-2: preoperative imlunestrant for er /her2- early stage breast cancer
-
2:37
elacestrant: a new weapon against advanced estrogen receptor-positive breast cancer
-
1:17
key trial updates in serds in er /her2- breast cancer from sabcs 2022
-
4:39
serd vs investigator’s choice of endocrine monotherapy for er /her2-advanced/mbc
-
4:06
serena-2: camizestrant vs fulvestrant in post-menopausal women with advanced er /her- breast cancer
-
0:30
the role of serds in the treatment landscape of patients with er /her2- breast cancer
-
2:29
window of opportunity elipse trial: elacestrant in postmenopausal women with er her2-/ early bc
-
5:47
elaine 1: las vs fulv in la er /her2- mbc esr1m disease progression on ai and cdk4/6i inhibitors
-
4:40
ameera-1 updates: amcenestrant plus palbociclib for patients with er /her2– advanced breast cancer